As part of its business strategy, EnVivo selectively forges partnerships to strengthen its pipeline as well as to accelerate and augment its development and commercialization efforts in certain geographies and indications.
Current partnerships include:
Nicotinic A7 Agonist Program – EnVivo has partnered with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, EVP-6124, in Japan and several other Asian countries.
HDAC Program – EnVivo is working collaboratively with the Michael J. Fox Foundation and the foundation’s Therapeutics Development Initiative on EVP-0334 research to develop a treatment for Parkinson’s disease.